{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:52:44Z","timestamp":1768639964753,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T00:00:00Z","timestamp":1501804800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s12032-017-1018-y","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T02:50:55Z","timestamp":1501815055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single \u201creal-world\u201d setting"],"prefix":"10.1007","volume":"34","author":[{"given":"Grace H.","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio A.","family":"Acuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Sevick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Brezden-Masley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"key":"1018_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392. doi: 10.1056\/NEJM200103153441101 .","journal-title":"N Engl J Med"},{"key":"1018_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ncponc1298","volume":"6","author":"G Mariani","year":"2009","unstructured":"Mariani G, Fasolo A, De Benedictis E, Gianni L. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol. 2009;6:93\u2013104. doi: 10.1038\/ncponc1298 .","journal-title":"Nat Clin Pract Oncol"},{"key":"1018_CR3","first-page":"1147","volume":"34","author":"A Sandoo","year":"2014","unstructured":"Sandoo A, Kitas GD, Carmichael AR. Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer. Anticancer Res. 2014;34:1147\u201351.","journal-title":"Anticancer Res"},{"key":"1018_CR4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1185\/03007995.2013.807232","volume":"29","author":"MAN Sendur","year":"2013","unstructured":"Sendur MAN, Aksoy S, Altundag K. Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin. 2013;29:1015\u201324. doi: 10.1185\/03007995.2013.807232 .","journal-title":"Curr Med Res Opin"},{"key":"1018_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ctrv.2013.04.002","volume":"40","author":"J Albanell","year":"2014","unstructured":"Albanell J, Ciruelos EM, Lluch A, Mu\u00f1oz M, Rodr\u00edguez CA. Trastuzumab in small tumours and in elderly women. Cancer Treat Rev. 2014;40:41\u20137. doi: 10.1016\/j.ctrv.2013.04.002 .","journal-title":"Cancer Treat Rev"},{"key":"1018_CR6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673\u201384. doi: 10.1056\/NEJMoa052122 .","journal-title":"N Engl J Med"},{"key":"1018_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1517\/14740331003627441","volume":"9","author":"J Chien","year":"2010","unstructured":"Chien J, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf. 2010;9:335\u201346. doi: 10.1517\/14740331003627441 .","journal-title":"Expert Opin Drug Saf"},{"key":"1018_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/2042098614529603","volume":"5","author":"AA Onitilo","year":"2014","unstructured":"Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf. 2014;5:154\u201366. doi: 10.1177\/2042098614529603 .","journal-title":"Ther Adv Drug Saf"},{"key":"1018_CR9","first-page":"70","volume":"16","author":"M Zeglinski","year":"2011","unstructured":"Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumab-induced cardiac dysfunction: a \u201cdual-hit\u201d. Exp Clin Cardiol. 2011;16:70\u20134.","journal-title":"Exp Clin Cardiol"},{"key":"1018_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","volume":"37","author":"T Chen","year":"2011","unstructured":"Chen T, Xu T, Li Y, Liang C, Chen J, Lu Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev. 2011;37:312\u201320. doi: 10.1016\/j.ctrv.2010.09.001 .","journal-title":"Cancer Treat Rev"},{"key":"1018_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216639755","author":"L Grazziotin","year":"2016","unstructured":"Grazziotin L, Picon P. Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer. J Oncol Pharm Pract. 2016;. doi: 10.1177\/1078155216639755 .","journal-title":"J Oncol Pharm Pract"},{"key":"1018_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","volume":"18","author":"L Tarantini","year":"2012","unstructured":"Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Cardiac Fail. 2012;18:113\u20139. doi: 10.1016\/j.cardfail.2011.10.015 .","journal-title":"J Cardiac Fail"},{"issue":"16","key":"1018_CR13","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa1203165","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659\u201372. doi: 10.1056\/NEJMoa1203165 .","journal-title":"N Engl J Med"},{"key":"1018_CR14","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","volume":"29","author":"EA Perez","year":"2011","unstructured":"Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366\u201373. doi: 10.1200\/JCO.2011.35.0868 .","journal-title":"J Clin Oncol"},{"issue":"14","key":"1018_CR15","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"key":"1018_CR16","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Eiermann W, Robert NJ, et al. Ten-year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive early breast cancer patients. 2015 San Antonio Breast Cancer Symposium. Abstract S5-04. Presented 11 December 2015.","DOI":"10.1158\/1538-7445.SABCS15-S5-04"},{"key":"1018_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2407-7-153","volume":"7","author":"GA Viani","year":"2007","unstructured":"Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153. doi: 10.1186\/1471-2407-7-153 .","journal-title":"BMC Cancer"},{"key":"1018_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1634\/theoncologist.2015-0125","volume":"20","author":"AF Yu","year":"2015","unstructured":"Yu AF, Yadav NU, Eaton AA, Lung BY, Thaler HT, Liu JE, et al. Continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction. Oncologist. 2015;20:1105\u201310. doi: 10.1634\/theoncologist.2015-0125 .","journal-title":"Oncologist"},{"key":"1018_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-013-2732-6","volume":"142","author":"G Fried","year":"2013","unstructured":"Fried G, Regev T, Moskovitz M. Trastuzumab-related cardiac events in the treatment of early breast cancer. Breast Cancer Res Treat. 2013;142:1\u20137. doi: 10.1007\/s10549-013-2732-6 .","journal-title":"Breast Cancer Res Treat"},{"key":"1018_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-008-0260-6","volume":"117","author":"D Wadhwa","year":"2009","unstructured":"Wadhwa D, Fallah-Rad N, Grenier D, Krahn M, Fang T, Ahmadie R, et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat. 2009;117:357\u201364. doi: 10.1007\/s10549-008-0260-6 .","journal-title":"Breast Cancer Res Treat"},{"key":"1018_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-015-0070-y","author":"LR Ayres","year":"2015","unstructured":"Ayres LR, de Almeida Campos MS, de Oliveira Gozzo T, Martinez EZ, Ungari AQ, de Andrade JM, et al. Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital. Int J Clin Pharm. 2015;. doi: 10.1007\/s11096-015-0070-y .","journal-title":"Int J Clin Pharm"},{"key":"1018_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214567162","author":"M Gunaldi","year":"2015","unstructured":"Gunaldi M, Duman BB, Afsar CU, Paydas S, Erkisi M, Kara IO, et al. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: an observational single-centre study. J Oncol Pharm Pract. 2015;. doi: 10.1177\/1078155214567162 .","journal-title":"J Oncol Pharm Pract"},{"key":"1018_CR23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cardfail.2009.04.011","volume":"15","author":"M Guglin","year":"2009","unstructured":"Guglin M, Hartlage G, Reynolds C, Chen R, Patel V. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Cardiac Fail. 2009;15:651\u20137. doi: 10.1016\/j.cardfail.2009.04.011 .","journal-title":"J Cardiac Fail"},{"key":"1018_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5114\/aoms.2012.28549","volume":"8","author":"G Piotrowski","year":"2012","unstructured":"Piotrowski G, Gawor R, Stasiak A, Gawor Z, Potemski P, Banach M. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: a prospective study. Arch Med Sci. 2012;8:227\u201335. doi: 10.5114\/aoms.2012.28549 .","journal-title":"Arch Med Sci"},{"key":"1018_CR25","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","volume":"27","author":"MY Halyard","year":"2009","unstructured":"Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol. 2009;27:2638\u201344. doi: 10.1200\/JCO.2008.17.9549 .","journal-title":"J Clin Oncol"},{"key":"1018_CR26","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24:4107\u201315. doi: 10.1200\/JCO.2005.04.9551 .","journal-title":"J Clin Oncol"},{"key":"1018_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.canrad.2014.01.001","volume":"18","author":"L Cao","year":"2014","unstructured":"Cao L, Hu WG, Kirova YM, Yang ZZ, Cai G, Yu XL, et al. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy. Cancer Radiother. 2014;18:119\u201324. doi: 10.1016\/j.canrad.2014.01.001 .","journal-title":"Cancer Radiother"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-017-1018-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T21:05:25Z","timestamp":1569963925000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-017-1018-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1007\/s12032-017-1018-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,4]]},"article-number":"154"}}